Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.

Andreas BleslLukas BinderChristoph HögenauerHeimo WenzlAndrea BorenichGudrun PregartnerAndrea BergholdSigrid MestelPatrizia KumpFranziska Baumann-DurchscheinWolfgang Petritsch

Published in: Alimentary pharmacology & therapeutics (2021)

Long-term treatment persistence of first anti-TNF therapy was limited in patients with inflammatory bowel diseases, primarily due to treatment failure and side effects.

Keyphrases

rheumatoid arthritis
stem cells
cell therapy